Friday, February 12, 2016

Ex-Synthes executives to be sentenced in late November

Ex-Synthes executives to be sentenced in late November for their role in an illegal clinical trial of bone cement used in spinal surgery.

Ex-Synthes executives to be sentenced in late November


Four former executives of the medical-device manufacturer Synthes Inc., each of whom pleaded guilty to a misdemeanor charge stemming from an illegal clinical trial of a bone cement, will be sentenced in late November, according to court records.

Three people died on the operating table during spinal operations involving the cement, which had not been approved by the FDA for that purpose.

Thomas B. Higgins and Michael D. Huggins are scheduled for sentencing Nov. 21, while Richard E. Bohner and John J. Walsh are scheduled for sentencing Nov. 22.

Swiss-based Synthes, which has facilities in Chester County, and its former wholly owned subsidiary, Norian, paid $23 million in fines in 2010 to settle the corporate charges brought by the U.S. Attorney’s Office in Philadelphia. In April, Synthes agreed to be bought by Johnson & Johnson for $21.3 billion.

Update: Adam Hoffinger, the attorney for Thomas Higgins, declined to comment on the case.

The June 5 Inquirer story on this topic can be found here.

Staff Writer
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy: comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
comments powered by Disqus
About this blog
David Sell blogs about the region's pharmaceutical industry. Follow him on Facebook.

Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Reach David at or 215-854-4506.

David Sell Staff Writer
Also on
letter icon Newsletter